Lipocine Inc.
LPCN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | -$0 | $0 | $0 |
| % Growth | 492.8% | -670.2% | -96.9% | – |
| Gross Profit | $0 | -$0 | -$0 | $0 |
| % Margin | 100% | 456.9% | -1,611.4% | 52.5% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -9.9% | 628% | -2,144.3% | -2.7% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 0.1% | 573.6% | -2,151.7% | -3.9% |
| EPS Diluted | -0.002 | -3.14 | -2.05 | -0.12 |
| % Growth | 99.9% | -53.2% | -1,608.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |